News
KRYS
306.48
+2.66%
7.93
Weekly Report: what happened at KRYS last week (1109-1113)?
Weekly Report · 2d ago
Krystal Biotech Earnings Call Signals Durable Growth and Pipeline Progress
TipRanks · 3d ago
How $400 Million Buyback Will Impact Krystal Biotech (KRYS) Stock
Simply Wall St · 5d ago
Krystal Biotech (KRYS), What Is Behind The Fresh Attention?
Simply Wall St · 6d ago
Weekly Report: what happened at KRYS last week (1102-1106)?
Weekly Report · 11/09 10:10
What Early Krystal Biotech Buyers Saw
Simply Wall St · 11/07 07:35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (TNDM), Sarepta Therapeutics (SRPT) and Krystal Biotech (KRYS)
TipRanks · 11/06 14:31
How Investors Are Reacting To Krystal Biotech (KRYS) Earnings Beat And Buyback
Simply Wall St · 11/05 05:29
Krystal Biotech (KRYS) Stock Jumps As Q3 Results Put Buyback First
Simply Wall St · 11/04 01:33
Krystal Biotech Is Maintained at Buy by Citigroup
Dow Jones · 11/03 18:49
Krystal Biotech Price Target Cut to $412.00/Share From $416.00 by Citigroup
Dow Jones · 11/03 18:49
Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412
Benzinga · 11/03 18:38
Krystal Biotech (KRYS) Stock Looks Above Fair Value On Current Earnings
Simply Wall St · 11/03 16:28
Krystal Biotech Is Maintained at Buy by TD Cowen
Dow Jones · 11/03 15:58
Krystal Biotech Price Target Cut to $380.00/Share From $403.00 by TD Cowen
Dow Jones · 11/03 15:58
TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380
Benzinga · 11/03 15:48
Krystal Biotech Price Target Cut to $375.00/Share From $400.00 by RBC Capital
Dow Jones · 11/03 15:13
Krystal Biotech Is Maintained at Outperform by RBC Capital
Dow Jones · 11/03 15:13
RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375
Benzinga · 11/03 15:02
Krystal Biotech price target lowered to $380 from $403 at TD Cowen
TipRanks · 11/03 13:40
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.